Poised to Challenge Need for Sleep, "Wakefulness Enhancer" Rouses Concerns.
- Published in:
- JAMA: Journal of the American Medical Association, 2004, v. 291, n. 2, p. 167, doi. 10.1001/jama.291.2.167
- By:
- Publication type:
- Article
Works matching DE "CEPHALON Inc."
Results: 33
1
2
Pipeline Preview.
- Published in:
- Formulary, 2008, v. 43, n. 6, p. 188
- Publication type:
- Article
3
New molecular entity: Treanda.
- Published in:
- Formulary, 2008, v. 43, n. 5, p. 156
- Publication type:
- Article
4
FDA actions in brief.
- Published in:
- Formulary, 2006, v. 41, n. 5, p. 213
- Publication type:
- Article
5
PsychRx.
- Published in:
- Psychiatry (1550-5952), 2010, v. 7, n. 4, p. 9
- Publication type:
- Article
6
Can sunshine cure the unhealthy entanglement of industry and health care?
- Published in:
- 2010
- By:
- Publication type:
- Editorial
7
RAISING CONTINGENT CAPITAL: THE CASE OF CEPHALON.
- Published in:
- Journal of Applied Corporate Finance, 2002, v. 15, n. 1, p. 57, doi. 10.1111/j.1745-6622.2002.tb00341.x
- By:
- Publication type:
- Article
8
Product Update.
- Published in:
- Journal of Psychosocial Nursing & Mental Health Services, 2006, v. 44, n. 6, p. 8
- Publication type:
- Article
9
FDA Recommends Additional Data for Sparlon.
- Published in:
- Journal of Psychosocial Nursing & Mental Health Services, 2006, v. 44, n. 5, p. 47
- Publication type:
- Article
10
EU Case Reports.
- Published in:
- Journal of Generic Medicines, 2011, v. 8, n. 3, p. 190, doi. 10.1177/1741134311422467
- By:
- Publication type:
- Article
11
EU Case Reports.
- Published in:
- Journal of Generic Medicines, 2011, v. 8, n. 2, p. 123, doi. 10.1177/1741134311408273
- By:
- Publication type:
- Article
12
Deal watch: Anti-IL-5 antibody attracts Cephalon to agree option for Ception acquisition.
- Published in:
- 2009
- Publication type:
- journal article
13
Cephalon, Inc. optimistic about Sparlon approval.
- Published in:
- Brown University Psychopharmacology Update, 2006, v. 17, n. 9, p. 8
- Publication type:
- Article
14
From the FDA.
- Published in:
- Brown University Psychopharmacology Update, 2006, v. 17, n. 6, p. 8
- Publication type:
- Article
15
News updates.
- Published in:
- Brown University Psychopharmacology Update, 1996, v. 7, n. 2, p. 5
- Publication type:
- Article
16
CEPHALON RECEIVES FDA RESPONSE TO ITS SUPPLEMENTAL FENTORA APPLICATION.
- Published in:
- Journal of Pain & Palliative Care Pharmacotherapy, 2008, v. 22, n. 4, p. 367
- Publication type:
- Article
17
BUCCAL FENTANYL TABLET RECEIVES FDA APPROVABLE LETTER FOR BREAKTHROUGH CANCER PAIN.
- Published in:
- Journal of Pain & Palliative Care Pharmacotherapy, 2007, v. 21, n. 1, p. 117
- Publication type:
- Article
18
SAFETY KIT AVAILABLE FOR PATIENTS USING ACTIQ.
- Published in:
- Journal of Pain & Palliative Care Pharmacotherapy, 2006, v. 20, n. 1, p. 82
- Publication type:
- Article
19
Treanda approved for chronic lymphocytic leukemia.
- Published in:
- American Journal of Health-System Pharmacy, 2008, v. 65, n. 9, p. 793, doi. 10.2146/news080034
- By:
- Publication type:
- Article
20
Partnerships in discovery.
- Published in:
- Chemistry & Industry, 2003, n. 2, p. 16
- By:
- Publication type:
- Article
21
From the FDA.
- Published in:
- Brown University Child & Adolescent Psychopharmacology Update, 2005, v. 7, n. 12, p. 8
- Publication type:
- Article
22
WHY CHOOSE MODAFINIL FOR EXCESSIVE DAYTIME SLEEPINESS?
- Published in:
- Issues in Mental Health Nursing, 2007, v. 28, n. 3, p. 313, doi. 10.1080/01612840601174110
- By:
- Publication type:
- Article
23
Teva hits bull's eye with Cephalon.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 7, p. 561, doi. 10.1038/nbt0711-561a
- By:
- Publication type:
- Article
24
Cephalon splashes out on mesenchymal stem cells.
- Published in:
- Nature Biotechnology, 2011, v. 29, n. 2, p. 97, doi. 10.1038/nbt0211-97a
- By:
- Publication type:
- Article
25
News in brief.
- Published in:
- Nature Biotechnology, 2006, v. 24, n. 12, p. 1463, doi. 10.1038/nbt1206-1463
- Publication type:
- Article
26
The biotech drug market.
- Published in:
- Nature Biotechnology, 2004, v. 22, n. 12, p. 1496, doi. 10.1038/nbt1204-1496
- By:
- Publication type:
- Article
27
Cephalon acquires Anesta.
- Published in:
- Nature Biotechnology, 2000, v. 18, n. 9, p. 912, doi. 10.1038/79326
- By:
- Publication type:
- Article
28
Regulatory Status of the Buccal Fentanyl sNDA Updated.
- Published in:
- Oncology (08909091), 2008, v. 22, n. 2, p. 204
- Publication type:
- Article
29
Positive Results Announced From Pivotal Study of Bendamustine in Non-Hodgkin's Lymphoma.
- Published in:
- Oncology (08909091), 2007, v. 21, n. 12, p. 1496
- Publication type:
- Article
30
Announcements.
- Published in:
- Oncology (08909091), 2006, v. 20, n. 11, p. 1466
- Publication type:
- Article
31
Fentanyl Buccal Tablet for the Treatment of Breakthrough Pain: Pharmacokinetics of Buccal Mucosa Delivery and Clinical Efficacy.
- Published in:
- Perspectives in Medicinal Chemistry, 2010, n. 4, p. 11, doi. 10.4137/PMC.S3928
- By:
- Publication type:
- Article
32
Recent Trends Involving CIAs Significantly Raise Stakes for Health Care Industry Participants.
- Published in:
- Journal of Health Care Compliance, 2009, v. 11, n. 2, p. 51
- By:
- Publication type:
- Article
33
Off-Label Marketing Prosecutions and Cephalon: The Government Hits Its Stride and Hits Hard.
- Published in:
- Journal of Health Care Compliance, 2009, v. 11, n. 1, p. 55
- By:
- Publication type:
- Article